The new study has discovered that six micro RNAs get upregulated in colon cancer cells and that the levels of these were controlled by a master regulator protein named CDX2.
New Delhi: Colon cancer is one of the most common types of cancer–both in India and worldwide. According to the Indian Council of Medical Research (ICMR), it is the third most common cancer in men (6, 63,000 cases in 2014, 10.0% of all cancer cases) and the second most common in women (5, 71,000 cases in 2014, 9.4% of all cancer cases).
Presently, colon cancer gets detected at very late stages. There are two techniques to detect it; either CT colonography and colonoscopy or immunohistochemistry. While CT colonography involves low dose radiation, colonoscopy is an invasive process, whereas immunohistochemistry can be subjective and sometimes not reproducible.
A new collaborative study involving four institutes in India and one in France, led by Dr Sagar Sengupta at the National Institute of Immunology (NII), has discovered a new way to identify the disease even at Stage I, the earliest stage.
Dr Sengupta’s laboratory works on micro RNAs, which are small single-stranded non-coding RNA molecules, silence the expression of many proteins. The micro RNAs are known to bind to the messenger RNA molecules that code for the proteins and thereby either inactivate or destroy them.
The new study has discovered that six micro RNAs get upregulated in colon cancer cells and that the levels of these were controlled by a master regulator protein named CDX2.
Importantly, the upregulated micro RNAs, named `DNA damage sensitive micro RNA’s or `DDSM’s, were found to target a group of cellular proteins essential to maintain the pristine nature of genetic material within each cell of the body. Experiments involving laboratory mice confirmed that the cells have a greater tendency to form cancer if there is overexpression of these micro RNAs and consequent loss of these genome stabilizers.
The researchers have tested their findings on publicly available datasets in The Cancer Genome Atlas (TCGA) and in a cohort of colon cancer patients who had come to All India Institute of Medical Sciences (AIIMS), New Delhi, for treatment. Analysis was done with the available data of over 410 patients and the biopsy materials of 54 patients from AIIMS, New Delhi.
They found that the DDSMs were upregulated even in Stage I colon cancer tissues. The upregulation persisted up to the final Stage IV colon cancer. More importantly, increased expression of the DDSMs in cancer patients decreased the probability of their survival.
Speaking to India Science Wire, Dr Sengupta said, “We believe that the identified DDSMs can serve as an invaluable biomarker for colon cancer early detection process. We now have to determine whether the DDSMs can also be detected in patient blood samples. If that is possible, it would make colon cancer detection as simple as the detection of blood sugar in diabetic patients.”
Apart from NII and AIIMS, New Delhi, Regional Centre for Biotechnology, Faridabad, St. John’s Research Hospital, Bengaluru and the University of Strasbourg, France contributed to this study. A report on the work has been published in the Journal of Cell Science.
Courtesy: India Science Wire
